Quality & Regulatory Affairs Manager

Outcomes4Me has appointed Jim Longley as Chief Revenue Officer to lead its commercial expansion. Longley previously served as Senior Vice President of AI Partnerships at OpenEvidence and held senior commercial positions at GoodRx and Doximity over his two-decade healthcare technology career. The Boston-based company uses AI to support cancer patients through treatment decisions. It serves more than 400,000 patients and works with nine of the top 10 oncology pharmaceutical companies. Longley will oversee the revenue organisation as Outcomes4Me expands its life sciences partnerships. The appointment follows recent company milestones, including recognition in TIME's Best Inventions of 2025 and as a Fast Company World Changing Idea. Founder and CEO Maya Said cited Longley's track record scaling health tech companies to hundreds of millions in revenue through strategic partnerships.

Veteran health tech leader Jim Longley joins the Outcomes4Me executive team to accelerate growth and support mission of empowering patients with cancer. After scaling revenue at OpenEvidence, GoodRx, and Doximity, Longley steps into the role of Chief Revenue Officer at Outcomes4Me to lead the commercial team and drive further value for patients, providers, pharma, and diagnostic companies BOSTON, Sept. 14, 2026 - Outcomes4Me Inc., the leading direct-to-patient health technology company leveraging AI to revolutionize cancer care, announced today that Jim Longley, most recently the Senior Vice President: AI Partnerships at OpenEvidence, has joined Outcomes4Me as Chief Revenue Officer. With more than two decades of senior leadership experience across healthcare technology, commercial strategy, and business development, Jim will lead Outcomes4Me's revenue organization as the company enters its next exciting phase of growth and further expands its life sciences collaborations. Prior to OpenEvidence, where he focused on building partnerships at the intersection of AI and healthcare, Jim spent nearly five years at GoodRx, where he held progressively senior commercial leadership positions, ultimately serving as Senior Vice President and Head of Commercial. Before GoodRx, Jim spent over six years at Doximity, where he was a Vice President for Business Development and Product Innovation. "When I left my last role, I was planning to take a break from corporate life," said Longley. "But, the opportunity to immediately make a difference at Outcomes4Me quickly drew me back in. Outcomes4Me has proven that it can help patients living with cancer while also creating tremendous value for its pharma customers by getting their life-saving therapies to the right patient at the right time. It's rare in commercial roles within health tech to see the product's direct impact on patients. At Outcomes4Me, patient value is paramount which makes our commercial job easier because the team has created an active and engaged community of oncology patients eager to learn about new treatment options and take action. I have never seen this hyper-targeted ability to reach patients with such diagnosis specificity and I can't wait to bring Outcomes4Me's innovation to more partners." "Jim is a proven revenue leader who has scaled some of the most notable health tech companies to hundreds of millions of dollars in revenue through his unique ability to forge partnerships that are a win-win-win across the healthcare ecosystem: a win for patients, a win for providers, and a win for customers" said Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me. "I'm thrilled that Jim has chosen Outcomes4Me as the next step in his already accomplished professional journey. He is the exact leader we need at this point in our company. We're ready for exponential growth and Jim is just the person to get us there." Jim's appointment comes after an exciting quarter for Outcomes4Me. Recently, the company has achieved important milestones, including: * For the second year in a row, Outcomes4Me was honored on the Inc. 5000 list of fastest-growing private companies after experiencing 395% three-year growth. * The editorial teams from Fierce Pharma, Fierce Biotech, and Fierce Healthcare honored Outcomes4Me Founder and CEO Dr. Maya R. Said on the 2026 Fierce50 list, highlighting leaders driving innovation in healthcare. * The prestigious Prix Galien USA program recognized Outcomes4Me as a nominee for "Best Startup." * The Outcomes4Me clinical team integrated 10 National Comprehensive Cancer Network(R)(NCCN(R) updates into the Outcomes4Me platform, spanning bladder cancer, breast cancer, kidney cancer, non-small cell lung cancer, and prostate cancer. These NCCN Guidelines(R) updates ensure patients using the Outcomes4Me platform have access to the latest recommended treatment options, according to the NCCN(R). * The San Antonio Breast Cancer Symposium selected Outcomes4Me's poster "Are We Listening to Every Patient? Digital Tools, Patient-Reported Outcomes and Disparities in Breast Cancer" for a spotlight session at the annual event, scheduled for 7:00am CT on December 10, 2026. The Outcomes4Me team is attending Fierce Pharma Week September 14-17, 2026 in Philadelphia. Follow this link to request a meeting with the team. About Outcomes4Me Named to TIME's Best Inventions of 2025 and recognized as a Fast Company World Changing Idea, Outcomes4Me is the leading direct-to-patient platform for cancer care, supporting more than 400,000 patients from diagnosis through every stage of treatment. Its AI-driven platform integrates clinical guidelines, genomics, clinical trial matching, and symptom tracking to help patients make informed, confident decisions about their care, without fees or gatekeepers. With 9 of the top 10 oncology pharmaceutical companies as customers, Outcomes4Me generates unique, at-scale proprietary datasets and insights that accelerate innovation in cancer care, helping bring better treatments to more patients, faster. For more information, visit www.outcomes4me.com.